高盛-药明康德:从“可预测性”到“确定性”布局,2026年高确定性复合增长标的;9项评级调整,药明康德_XXDC上调至买入-From Betability to Position,Position for 2026 with higher-certainty compounders;9 rating changes,Wuxi App_XXDC to Buy-20260205【60页】

发表回复

后才能评论